|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Serotypes | 1 | 2 | 3 | 4 | 5 | 6A | 6B | 7F | 8 | 9N | 9V | 10A | 11A | 12F | 14 | 15B | 17F | 18C | 19A | 19F | 20 | 22F | 23F | 33F |
| Pneumovax | X\* | X | X\* | X\*7 | X\* | \* | X\*7 | X\* | X | X | X\*7 | X | X | X | X\*7 | X | X | X\*7 | X\* | X\*7 | X | X | X\*7 | X |

**Table I.** Green highlights denote serotypes that have antibody titers that have been validated and are commonly available. \*Denotes a serotype within the 13 valent conjugated pneumococcal vaccine, 7 denotes a serotype within the 7 valent pneumococcal vaccine. A normal response is considered titers ≥1.3 μg/mL or 4 fold increases in at least 50% (2 to 5 years) or 70% (>6 years) of serotypes tested.